SG11201408617PA - Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders - Google Patents

Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Info

Publication number
SG11201408617PA
SG11201408617PA SG11201408617PA SG11201408617PA SG11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA SG 11201408617P A SG11201408617P A SG 11201408617PA
Authority
SG
Singapore
Prior art keywords
alkyl
international
con
treatment
heterocyclyl
Prior art date
Application number
SG11201408617PA
Other languages
English (en)
Inventor
Johann Leban
Mirko Zaja
Original Assignee
4Sc Discovery Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Sc Discovery Gmbh filed Critical 4Sc Discovery Gmbh
Publication of SG11201408617PA publication Critical patent/SG11201408617PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/056Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG11201408617PA 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders SG11201408617PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664936P 2012-06-27 2012-06-27
EP12174669 2012-07-02
PCT/EP2013/063537 WO2014001464A1 (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Publications (1)

Publication Number Publication Date
SG11201408617PA true SG11201408617PA (en) 2015-01-29

Family

ID=49782305

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408617PA SG11201408617PA (en) 2012-06-27 2013-06-27 Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders

Country Status (19)

Country Link
US (2) US9580438B2 (zh)
EP (1) EP2867237A1 (zh)
JP (2) JP6272846B2 (zh)
KR (1) KR102155559B1 (zh)
CN (1) CN104540831B (zh)
AU (2) AU2013283318B2 (zh)
BR (1) BR112014032581A8 (zh)
CA (1) CA2877589C (zh)
EA (1) EA029718B1 (zh)
HK (1) HK1204474A1 (zh)
IL (1) IL236463A0 (zh)
IN (1) IN2014MN02562A (zh)
MX (1) MX350418B (zh)
MY (1) MY167785A (zh)
NZ (1) NZ702618A (zh)
SG (1) SG11201408617PA (zh)
UA (1) UA116541C2 (zh)
WO (1) WO2014001464A1 (zh)
ZA (1) ZA201409194B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN02562A (zh) * 2012-06-27 2015-07-24 4Sc Discovery Gmbh
CA2943231C (en) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
PT3119762T (pt) 2014-03-20 2021-08-31 Capella Therapeutics Inc Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
ES2838573T3 (es) 2014-08-21 2021-07-02 Bristol Myers Squibb Co Derivados de benzamida ligados como inhibidores potentes de ROCK
WO2017013210A1 (en) * 2015-07-21 2017-01-26 4Sc Ag Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds
WO2017053537A1 (en) 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
IL295649A (en) * 2016-04-07 2022-10-01 Glaxosmithkline Ip Dev Ltd Heterocyclic amides are useful as protein modulators
JP2021500394A (ja) 2017-10-27 2021-01-07 シャンハイ・ヤオ・ユアン・バイオテクノロジー・カンパニー・リミテッド αタンパク質キナーゼ1を活性化することによって免疫応答をモジュレートするための組成物および方法
US20220033418A1 (en) 2018-09-13 2022-02-03 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
CN109020990A (zh) * 2018-09-20 2018-12-18 广西壮族自治区药用植物园 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途
KR102119150B1 (ko) * 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
WO2021261601A1 (ja) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
CN116942819A (zh) * 2023-04-24 2023-10-27 珠海市人民医院 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167569A (en) 1976-12-09 1979-09-11 Imperial Chemical Industries Limited Pyrimido[1,2-a ]benzimidazole derivatives
CA2458533C (en) 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JO2724B1 (en) 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP5193876B2 (ja) 2005-12-02 2013-05-08 バイエル・ヘルスケア・エルエルシー オーロラキナーゼの阻害により癌を処置するために有用なピロロトリアジン誘導体
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2947073B1 (en) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
IN2014MN02562A (zh) * 2012-06-27 2015-07-24 4Sc Discovery Gmbh

Also Published As

Publication number Publication date
MX350418B (es) 2017-09-06
JP2018076360A (ja) 2018-05-17
CN104540831B (zh) 2017-11-07
EA201500050A1 (ru) 2015-09-30
US9580438B2 (en) 2017-02-28
MY167785A (en) 2018-09-25
CN104540831A (zh) 2015-04-22
EA029718B1 (ru) 2018-05-31
EP2867237A1 (en) 2015-05-06
UA116541C2 (uk) 2018-04-10
BR112014032581A8 (pt) 2018-08-14
JP6272846B2 (ja) 2018-01-31
NZ702618A (en) 2016-12-23
MX2014015938A (es) 2015-07-21
WO2014001464A1 (en) 2014-01-03
CA2877589C (en) 2019-11-26
AU2013283318A1 (en) 2015-01-22
ZA201409194B (en) 2017-08-30
US20150158878A1 (en) 2015-06-11
AU2013283318B2 (en) 2017-11-23
IN2014MN02562A (zh) 2015-07-24
IL236463A0 (en) 2015-02-26
KR20150037877A (ko) 2015-04-08
AU2018201275A1 (en) 2018-03-15
HK1204474A1 (zh) 2015-11-20
BR112014032581A2 (pt) 2017-06-27
US20170240556A1 (en) 2017-08-24
CA2877589A1 (en) 2014-01-03
JP2015525742A (ja) 2015-09-07
KR102155559B1 (ko) 2020-09-15

Similar Documents

Publication Publication Date Title
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408094YA (en) Neprilysin inhibitors
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11202000266VA (en) Quinoline derivatives for treating infections with helminths
SG11201809342YA (en) Pyrimidine compounds as jak kinase inhibitors
SG11201407837WA (en) Beta-hairpin peptidomimetics
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201903326RA (en) Liposomal formulation for use in the treatment of cancer
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201402986RA (en) Kinase inhibitors
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201809674QA (en) Adenine derivatives as protein kinase inhibitors
SG11201908235RA (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201805142RA (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative